Table 2.
Demographics of dogs enrolled in the survey and prevention studies
| Signalment | Survey study | Prevention study | ||
|---|---|---|---|---|
| All dogs (n = 1623) |
A. vasorum positive (n = 198) |
Placebo (n = 307) |
Simparica Trio®a (n = 315) |
|
| Purebred (%) | 1153 (71.0) | 125 (63.1) | 240 (78.2) | 237 (75.2) |
| Non-purebred (%) | 470 (29.0) | 73 (36.9) | 67 (21.8) | 78 (24.8) |
| Age mean (years) | 5.1 | 3.8 | 4.5 | 4.2 |
| Age range (years) | 0.1–16.0 | 0.1–14.0 | 0.2–15.0 | 0.2–13.0 |
| Body weight mean (kg) | nd | nd | 21.6 | 21.0 |
| Body weight range (kg) | nd | nd | 2.5–47.6 | 2.0–54.4 |
| Male (%) | 806 (49.7) | 110 (55.6) | 148 (48.2) | 144 (45.7) |
| Female (%) | 817 (50.3) | 88 (44.4) | 159 (51.8) | 171 (54.3) |
| Lives mostly indoors (%) | 106 (6.5) | 8 (4.0) | 10 (3.3) | 11 (3.5) |
| Lives mostly outdoors (%) | 609 (37.5) | 106 (53.5) | 120 (39.1) | 125 (39.7) |
| Lives indoors and outdoors (%) | 908 (55.9) | 84 (42.4) | 177 (57.7) | 179 (56.8) |
aSimparica Trio® provided 1.2 to 2.4 mg/kg sarolaner, 24 to 48 µg/kg moxidectin and 5 to 10 mg/kg pyrantel (as pamoate salt) oral doses per kg body weight
Abbreviation: nd, not determined